Results 31 to 40 of about 13,874 (194)

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation

Frontiers in Pediatrics, 2023
IntroductionPrimary infection or reactivation of Epstein-Barr Virus (EBV) is a significant cause of morbidity and mortality in pediatric kidney transplantation.
Elodie Cheyssac, Hamidou Savadogo, Nathan Lagoutte, Véronique Baudouin, Marina Charbit, Robert Novo, Anne-Laure Sellier-Leclerc, Marc Fila, Stéphane Decramer, Elodie Merieau, Ariane Zaloszyc, Jérôme Harambat, Gwenaelle Roussey   +12 more
doaj   +1 more source

Cytomegalovirus Reactivation During Therapy for Pediatric Acute Lymphoblastic Leukemia. [PDF]

J Med Virol
ABSTRACT Cytomegalovirus (CMV) reactivation is a recognized complication after hematopoietic stem cell transplantation, but its relevance during conventional chemotherapy for pediatric acute lymphoblastic leukemia (ALL) is poorly defined, especially in CMV‐prevalent regions. This retrospective cross‐sectional study was conducted at a tertiary pediatric
Melavarige Venkatagiri A, Reddy N, Chandwani R, Shekar N, Perampalli Manjunath S, Abdu Rahiman E, Mukhopadhyay C, Bhat Kalya V.   +7 more
europepmc   +2 more sources

Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Frontiers in Cellular and Infection Microbiology, 2022
Many antiviral agents have been studied in clinical trials for allograft rejection prevention following cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients. However, data on the most effective and safest treatment are lacking.
Narisa Ruenroengbun, Tunlanut Sapankaew, Kamolpat Chaiyakittisopon, Pakpoom Phoompoung, Thundon Ngamprasertchai   +4 more
doaj   +1 more source

Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation

Di-san junyi daxue xuebao, 2020
Objective and;To evaluate the clinical value of valganciclovir in preemptive treatment of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing the efficacy of the drug with other conventional ...
LU Xuan, YAN Han, XIA Linghui
doaj   +1 more source

Unraveling the Role of Allo-Antibodies and Transplant Injury. [PDF]

, 2016
Alloimmunity driving rejection in the context of solid organ transplantation can be grossly divided into mechanisms predominantly driven by either T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR), though the co-existence of both ...
Matsuda, Yoshiko, Sarwal, Minnie M
core   +2 more sources

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia

Transplantology, 2021
Cytomegalovirus (CMV) prophylaxis with valganciclovir is the standard of practice in most transplant centers, but treatment-related leukopenia can limit valganciclovir’s use.
Arindam Singha, Pamela K. Burcham, April Logan, Zeinab El Boghdadly, Molly M. Howsare, David R. Nunley, Mark E. Lustberg, Brian C. Keller   +7 more
doaj   +1 more source

Role of therapeutic drug monitoring in pulmonary infections : use and potential for expanded use of dried blood spot samples [PDF]

, 2015
Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment.
Akkerman, Onno W, Alffenaar, Jan-Willem C, Bolhuis, Mathieu S, Hofman, Susan, Koster, Remco A, Stove, Christophe, van Assen, Sander   +6 more
core   +2 more sources

Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. [PDF]

, 2007
BACKGROUND: Immunosuppressive and antiviral prophylactic drugs are needed to prevent acute rejection and infection after transplantation. We assessed the efficacy and safety of the introduction of universal valganciclovir prophylaxis in combination with ...
Fellay, J., Fontana, M., Manuel, O., Matter, M., Meylan, P.R., Pascual, M., Sturzenegger, N., Venetz, J.P., Wasserfallen, J.B.   +8 more
core   +1 more source

Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation [PDF]

, 2007
We employed antibody pre-conditioning with alemtuzumab and posttransplant immunosuppression with low-dose tacrolimus monotherapy in 26 consecutive pediatric kidney transplant recipients between January 2004 and December 2005. Mean recipient age was 10.7 ±
Basu, A, Ellis, D, Erkan, E, Gray, EA, Grosso, MJ, James, G, Kayler, LK, Marcos, A, McFeaters, CG, Moritz, ML, Shapiro, R, Starzl, TE, Tan, HP, Vats, AN, Zeevi, A   +14 more
core   +1 more source

Experience of Using the Antiviral Therapy of Generalized Congenital Cytomegalovirus Infection

Детские инфекции (Москва), 2016
The article presents the results of observation and treatment with ganciclovir and oral valganciclovir form of a premature infant with congenital generalized symptomatic cytomegalovirus infection (CMVI) involving pathology of CNS, cholangitis ...
G. V. Petrova, V. I. Shakhgildyan, E. A. Chistozvonova, T. A. Pugacheva, N. V. Turkot, M. V. Egorova, O. U. Sautenko, I. B. Astasheva, O. V. Romanova, N. V. Kostycheva, T. A. Grigorieva, M. G. Kulagina   +11 more
doaj   +1 more source